OSR Health brings together a diversified portfolio of subsidiary companies spanning immuno-oncology, biologics, MedTech, and device distribution. This diversity not only reduces reliance on any single technology, modality, or manufacturing pathway, but also allows each program to navigate distinct global regulatory frameworks, further mitigating risk across the portfolio.

What unites us is our singular strategic focus: making healthcare simpler, more accessible, and less burdensome. By aligning our platforms around this vision, we deliver meaningful impact for patients, streamline care for healthcare providers, and create lasting benefits for society as a whole. Simplification through innovation.

Simplification Through Innovation

OSR Health brings together a diversified portfolio of subsidiary companies spanning immuno-oncology, biologics, MedTech, and device distribution. This diversity not only reduces reliance on any single technology, modality, or manufacturing pathway, but also allows each program to navigate distinct global regulatory frameworks, further mitigating risk across the portfolio.

What unites us is our singular strategic focus: making healthcare simpler, more accessible, and less burdensome. By aligning our platforms around this vision, we deliver meaningful impact for patients, streamline care for healthcare providers, and create lasting benefits for society as a whole. Simplification through innovation.

Examples of lead programs that aim to achieve OSR Health's vision of simplifying healthcare:

VXM01: From IV to Oral Dosing →

- Replacing complex hospital infusions with an oral vaccine. Cheaper, easier, scalable

DRT-101: From Pain to Pain-free →
- Disease-modifying drug to prevent major invasive joint replacement surgeries

Glucheck: From Pain to Passive →
- Non-invasive monitoring eliminates the pain and burden of daily finger pricks

4PL: From Fragmented to Integrated →
- Reducing regulatory, financial and logistical complexity in medical device distribution

Impact in Action

Examples of lead programs that aim to achieve OSR Health's vision of simplifying healthcare:

VXM01: From IV to Oral Dosing →

- Replacing complex hospital infusions with an oral vaccine. Cheaper, easier, scalable

DRT-101: From Surgery to Pill →
- Disease-modifying drug to prevent major invasive joint replacement surgeries

Glucheck: From Pain to Passive →
- Non-invasive monitoring eliminates the pain and burden of daily finger pricks

4PL: From Fragmented to Integrated →
- Reducing regulatory, financial and logistical complexity in medical device distribution

Who is eligible to participate in the Shareholder Loyalty CVR Program?

All shareholders who own OSR Health common stock as of the applicable Record Date are eligible to apply for the Shareholder Loyalty CVR Program. Shareholders must complete the required enrollment process and satisfy the applicable program requirements before Contingent Value Rights (CVRs) are issued.

How do I enroll?

Enrollment is completed by submitting the appropriate application form. U.S. shareholders will need to hold their shares through Direct Registration (DRS) with the Company's transfer agent before enrolling. Non-U.S. shareholders enroll through a separate application process. Full instructions and forms are available on this page.

What happens if I sell my shares?

The Shareholder Loyalty CVR Program is designed to reward long-term ownership. If you sell, transfer, or otherwise dispose of the shares associated with your CVRs before the applicable milestone is achieved, those CVRs will generally terminate and will no longer be eligible to receive additional shares.

Extra shares recieved by reaching are milestones are free to be sold and don't affect future milestone rewards associated with the CVRs from the original shares held on record date.

Do I need to do anything after enrolling?

Once your enrollment has been approved, no further action is generally required. Simply continue to hold your enrolled shares and remain eligible under the terms of the program. If applicable share price milestones are achieved during the program period, eligible U.S. shareholders will receive the corresponding share distributions in accordance with the program terms. Non U.S. shareholders will have to provide a broker attestation on each measurement date to confirm their original shares position.